Lupus
ANA multiplex testing overutilized, 'straying further' from Choosing Wisely guidelines
Contrary to Choosing Wisely recommendations, indiscriminate and high use of antinuclear antibodies multiplex testing has fostered widespread unfamiliarity of what it tests for and how to interpret its results, noted a presenter here.
Myasthenia gravis plus thymectomy increases risk for lupus
Patients with myasthenia gravis — particularly those post-thymectomy — demonstrate an increased odds for having systemic lupus erythematosus, according to a speaker at the 2021 North American Young Rheumatology Investigator Forum.
Nearly half of systemic lupus erythematosus risk may be reduced by healthy lifestyle
Healthy lifestyle behaviors could potentially reduce the risk for systemic lupus erythematosus by nearly half, according to data published in Arthritis & Rheumatology.
Study examines risk factors for systemic lupus erythematosus development
‘What we see that kills patients’: Managing cardiovascular event risk in lupus nephritis
Managing cardiovascular event risk is critical to preventing morbidity and mortality in lupus nephritis, especially among groups at increased risk for the disease, according to a speaker at the 2021 Rheumatology Nurses Society annual conference.
A decade under Benlysta: Review touts how historic lupus drug continues to impact therapy
In the 10 years since its first FDA approval for systemic lupus erythematosus in 2011, belimumab has altered the “SLE treatment paradigm,” amassing a body of evidence establishing it as a disease-modifying therapy, according to a review article.
FDA approves Saphnelo, first new lupus treatment since 2011
The FDA has approved AstraZeneca’s anifrolumab-fnia, a first-in-class type I interferon receptor antagonist, for treatment of adults with moderate to severe systemic lupus erythematosus, according to a press release.
CARRA, PReS issue guidance for corticosteroid dosing in childhood-onset lupus nephritis
Patients with childhood-onset lupus nephritis should receive up to three infusions of methylprednisolone at 30 mg/kg per dose upon diagnosis, with a maximum 60 mg of daily oral corticosteroids in the first 4 weeks, according to researchers.
Lupus-related neuropsychiatric events linked to active disease, corticosteroids
Neuropsychiatric events caused by systemic lupus erythematosus are associated with active disease, male sex, corticosteroids and concurrent non-lupus events, except headaches, according to data published in Arthritis & Rheumatology.
Less than 10% of Medicaid patients with lupus vaccinated against preventable disease
Less than 10% of Medicaid beneficiaries with systemic lupus erythematosus are vaccinated against preventable diseases such as influenza, herpes zoster, cervical cancer and others, according to data published in Arthritis Care & Research.